伊马替尼为基础化疗治疗新诊断BCR-ABL阳性急性淋巴细胞白血病的II期研究
这项II期试验纳入68例新诊断BCR-ABL阳性急性淋巴细胞白血病成人患者,接受伊马替尼联合化疗。65例达完全缓解(95.6%),估计2年无事件生存率和总生存率分别为62.3%和67.4%,43例在首次完全缓解时接受异基因造血干细胞移植。
要点
- 68例患者中65例达完全缓解,完全缓解率95.6%
- 估计2年无事件生存率62.3%,总生存率67.4%
- 43例在首次完全缓解时接受异基因造血干细胞移植
核心结论
- 伊马替尼为基础化疗观察到高完全缓解率,使高比例患者能够接受异基因造血干细胞移植,尤其是55岁以下患者。
- 强化巩固治疗降低了诱导治疗后的早期复发率,并改善了异基因造血干细胞移植后的总生存率和无事件生存率。
研究设计与样本
- II期试验,纳入2008年10月至2010年12月间新诊断BCR-ABL阳性急性淋巴细胞白血病成人患者68例。
- 中位年龄49岁,其中28例年龄大于55岁。
- 试验注册号为UMIN 000001226。
主要发现
- 65例患者达完全缓解(95.6%)。
- 估计2年无事件生存率为62.3%,估计2年总生存率为67.4%。
- 43例在首次完全缓解时接受异基因造血干细胞移植;39例55岁以下患者中35例、26例55岁以上患者中8例在首次完全缓解时接受异基因造血干细胞移植。
- 3年总生存率:55岁以下首次完全缓解接受移植组80.4%,55岁以上首次完全缓解接受移植组41.1%,55岁以下首次完全缓解未接受移植组32.5%,55岁以上首次完全缓解未接受移植组52.0%(P = 0.058)。
- 3年无事件生存率:上述四组分别为76.7%、53.6%、未达到、26.4%(P = 0.150)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults. Sixty-eight patients were included in the trial between October 2008 and December 2010. The median age was 49 years, with 28 patients >55 years of age. Sixty-five patients achieved CR (95.6%). The estimated 2-year event-free survival (EFS) and overall survival (OS) were 62.3% and 67.4%, respectively. Allogeneic stem cell transplantation (allo-SCT) at initial CR was performed in 43 patients. Thirty-five of 39 patients <55 years and 8 of 26 patients >55 years underwent allo-SCT at first CR. The 3-year OS in patients <55 years receiving allo-SCT at first CR, patients >55 years receiving allo-SCT at first CR, patients <55 years not receiving allo-SCT at first CR, and patients >55 years not receiving allo-SCT at first CR were 80.4%, 41.1%, 32.5%, and 52.0%, respectively (P = 0.058). The three-year EFS in each group was 76.7%, 53.6%, not reached, and 26.4%, respectively (P = 0.150). A high CR rate was observed with imatinib-based chemotherapy allowing allo-SCT in a high proportion of patients, particularly those <55 years. Moreover, intensified consolidation therapy reduced early relapse rates following induction therapy and resulted in improved OS and EFS rates following allo-SCT. This trial was registered with the UMIN (000001226).
引用
- Fujisawa S, Mizuta S, Akiyama H, et al. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017. PMID: 28103625. doi:10.1002/ajh.24653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。